Tigecycline in the treatment of complicated intra-abdominal and complicated skin and skin structure infections.

Published

Journal Article

Tigecycline, a glycylcycline related to the tetracycline class of antibiotics, represents a new option for the treatment of complicated intra-abdominal and complicated skin and skin structure infections. It displays favorable activity in vitro against the most common causative Gram-positive, Gram-negative and anaerobic pathogens. In addition, tigecycline demonstrates activity against drug-resistant pathogens such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococci, and organisms (such as Escherichia coli and Klebsiella pneumoniae) producing extended-spectrum beta-lactamases. Tigecycline lacks activity in vitro against Pseudomonas and Proteus spp. In randomized clinical trials, tigecycline administered intravenously twice daily has demonstrated efficacy similar to comparators for a variety of complicated skin and skin structure and complicated intra-abdominal infections. The potential for significant drug interactions with tigecycline appears to be minimal. Dosing adjustment is needed for patients with severe hepatic impairment. The predominant side effect associated with its use to date has been gastrointestinal intolerance (nausea and vomiting).

Full Text

Duke Authors

Cited Authors

  • Townsend, ML; Pound, MW; Drew, RH

Published Date

  • December 2007

Published In

Volume / Issue

  • 3 / 6

Start / End Page

  • 1059 - 1070

PubMed ID

  • 18516315

Pubmed Central ID

  • 18516315

International Standard Serial Number (ISSN)

  • 1176-6336

Language

  • eng

Conference Location

  • New Zealand